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lent users was only significant between lovastatin and
pravastatin. 
 
CONCLUSION:
 
 Pravastatin is associated with
less healthcare resource utilization in new users, possibly
due to lack of interaction effects. In prevalent users, the
differences were minimized, possibly due to adjustments
in drug and dosage regimens.
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Much of research on the costs of diabetes mellitus has fo-
cused on long-term complications. There are limited data
on the factors associated with acute diabetes-related
events. OBJECTIVE: The goal of this study was to iden-
tify predictors of acute diabetes complications in a man-
aged-care setting. METHODS: Using a retrospective co-
hort design and a database that linked medical claims
and clinical laboratory data, adult members of a New
England health plan with a diagnosis of diabetes mellitus
between January 1, 1994 through June 30, 1998 were
identified. Inpatient admissions with diagnoses consistent
with acute (“short-term”) diabetes complications (repre-
sented primarily by hyperglycemia, hypoglycemia, and
selected infections) were then evaluated, and expressed
on a 3-year basis. Stratified and multivariate logistic re-
gression analyses were employed to determine the influ-
ence of key factors, such as age, gender, mean glycosy-
lated hemoglobin (HbA1c) value, whether the patient
had a diagnosis of cancer, and whether the patient had
long-term diabetes complications, on the risk of inpatient
admission. RESULTS: Of 2,394 patients with diabetes
mellitus, approximately 11% (269) had at least one inpa-
tient stay for an acute complication over 3 years. The risk
of inpatient treatment for short-term complications was
found to increase 22% (odds ratio 1.22, P  0.01) for
every one point increase in HbA1c. In addition, advanc-
ing age (odds ratios of 1.63 and 2.56 for patients 60 to
69 years and 70 years relative to under 50 years, re-
spectively; both P  0.05), long-term complications
(odds ratio 9.39, P  0.01), and cancer (odds ratio 3.13,
P  0.01) all were associated with increasing risk. CON-
CLUSIONS: In clinical practice, we found that poorer
glycemic control, age, and comorbidity are independent
risk factors for acute diabetes complications. Further re-
search is needed to determine whether better risk-factor
management (e.g., control of HbA1c) can reduce the rate
of acute diabetes complications.
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In 1996 the FDA approved donepezil for treatment of
Alzheimer’s patients with symptoms of memory and cog-
nitive loss. A recent study projected that the cost of done-
pezil could be offset by reduced utilization over a two-
year period. OBJECTIVES: The purpose of this study
was to measure use of donepezil among Veteran’s Health
Administration (VHA) patients during FY’98 and the im-
pact on cost. METHODS: Patients diagnosed with
Alzheimer’s disease in five VHA medical centers were
identified and costs for inpatient and outpatient care
were calculated based on Medicare reimbursement rates.
Extended care costs were calculated at $236 per day
(VHA national per diem). Prescription costs were calcu-
lated using VHA Pharmacy Benefit Management prices.
Patients with medical contraindications, those who died
during the study period, and those admitted to an ex-
tended care facility prior to the beginning of the fiscal
year, were excluded from the analysis. Regression analy-
sis was used to measure the association between done-
pezil use and cost while controlling for severity, comor-
bidity, previous hospitalizations, and site. RESULTS:
Donepezil was used by 11% (167) of patients with no
contraindications (N  1484). The regression analyses
indicated donepezil users had higher pharmaceutical
($800, P  0.0001) and outpatient costs ($801, P 
0.006), but lower inpatient (acute plus extended care)
costs ($1542, P  0.10). There was no substantial dif-
ference in total cost ($58, P  0.95). CONCLUSION:
The results support the hypothesis that higher pharma-
ceutical and outpatients costs related to donepezil use are
offset by lower inpatient costs. The extent of the offset
may be greater for the VHA (due to substantial discounts
with drug manufacturers), than would be found in other
health care systems.
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OBJECTIVE: The objective of this study was to compare
survival and costs before and after the availability of
